Stock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| Ficerafusp alfa + Pembrolizumab | 1L recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) | Phase 2/3 | Aug 15, 2027 | — |
| Ficerafusp alfa -/+ Pembrolizumab | 3L+ metastatic colorectal cancer (RAS/B-Rapidly Accelerated Fibrosarcoma (BRAF) wild type) | Phase 1b | Dec 31, 2026 | — |
Upcoming milestones
Company profile
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
3L+ metastatic colorectal cancer (RAS/B-Rapidly Accelerated Fibrosarcoma (BRAF) wild type)
1L recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Data readout